The World Health Organisation (WHO) has said that additional clarifications from manufacturer are needed to conduct a final Emergency Use Listing (EUL) risk-benefit assessment for global use of India-made COVAXIN.
“Technical Advisory Group (TAG) for Emergency Use Listing has decided that additional clarifications from the manufacturer are needed to conduct a final EUL risk-benefit assessment for global use of the vaccine,” the WHO said.